Cargando…

Trends of denosumab-related publications in web of science

Denosumab is a human monoclonal antibody that targets nuclear factor-kappa B ligand and is highly effective in blocking bone resorption. Bibliometrics can intuitively show the research development process, research status, research hotspots and development trend of a certain topic for researchers. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Xiaohong, Xie, Tianyu, Feng, Wenyu, Qin, Zhaojie, Liao, Shijie, Liu, Yun, Lu, Shenglin, He, Mingwei, Wei, Qingjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876013/
https://www.ncbi.nlm.nih.gov/pubmed/36705356
http://dx.doi.org/10.1097/MD.0000000000032784
_version_ 1784878075217969152
author Jiang, Xiaohong
Xie, Tianyu
Feng, Wenyu
Qin, Zhaojie
Liao, Shijie
Liu, Yun
Lu, Shenglin
He, Mingwei
Wei, Qingjun
author_facet Jiang, Xiaohong
Xie, Tianyu
Feng, Wenyu
Qin, Zhaojie
Liao, Shijie
Liu, Yun
Lu, Shenglin
He, Mingwei
Wei, Qingjun
author_sort Jiang, Xiaohong
collection PubMed
description Denosumab is a human monoclonal antibody that targets nuclear factor-kappa B ligand and is highly effective in blocking bone resorption. Bibliometrics can intuitively show the research development process, research status, research hotspots and development trend of a certain topic for researchers. This study assessed the course of research and development for denosumab in terms of publications over the past 2 decades. Web of Science databases were searched to identify publications related to research on denosumab from January 1, 2005 to December 31, 2022. The VOS Viewer software (version 1.6.17) and Bibliometrix package in R (version 4.1.3) were used in this study. There were 5119 denosumab-related publications during this period. The total number of citations of denosumab-related publications reached 94917. The most articles were published in the field of Endocrinology Metabolism. As an international language, English remains the most popular language for writing papers. Five of the top ten institutions originated in the USA. Through the VOS Viewer analysis, we found that the relationships between Amgen Inc. with its collaborations were grouped into 4 clusters, the USA was the mainland for research and development on denosumab, closely collaborating with many other countries, such as Canada, Japan, England, and China. Wagman RB from USA was the most prolific author with 119 publications. The journal with the most publications was Osteoporosis International (481 publications). The most cited article was “Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis” with 2053 citations. The clinical trial comprised 6 of the 10 most frequently cited publications, and the rest consisted of reviews. The most frequent keywords for publications since January 1, 2014 were “prevention” and “management,” indicating that a number of prevention and management measures have been developed to regulate the use of denosumab in treating osteoporosis. Our research provided a comprehensive review of denosumab-related publications, suggesting that the development of denosumab is a long process and numerous clinical trials have been conducted before applications in clinical settings.
format Online
Article
Text
id pubmed-9876013
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-98760132023-01-27 Trends of denosumab-related publications in web of science Jiang, Xiaohong Xie, Tianyu Feng, Wenyu Qin, Zhaojie Liao, Shijie Liu, Yun Lu, Shenglin He, Mingwei Wei, Qingjun Medicine (Baltimore) 7400 Denosumab is a human monoclonal antibody that targets nuclear factor-kappa B ligand and is highly effective in blocking bone resorption. Bibliometrics can intuitively show the research development process, research status, research hotspots and development trend of a certain topic for researchers. This study assessed the course of research and development for denosumab in terms of publications over the past 2 decades. Web of Science databases were searched to identify publications related to research on denosumab from January 1, 2005 to December 31, 2022. The VOS Viewer software (version 1.6.17) and Bibliometrix package in R (version 4.1.3) were used in this study. There were 5119 denosumab-related publications during this period. The total number of citations of denosumab-related publications reached 94917. The most articles were published in the field of Endocrinology Metabolism. As an international language, English remains the most popular language for writing papers. Five of the top ten institutions originated in the USA. Through the VOS Viewer analysis, we found that the relationships between Amgen Inc. with its collaborations were grouped into 4 clusters, the USA was the mainland for research and development on denosumab, closely collaborating with many other countries, such as Canada, Japan, England, and China. Wagman RB from USA was the most prolific author with 119 publications. The journal with the most publications was Osteoporosis International (481 publications). The most cited article was “Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis” with 2053 citations. The clinical trial comprised 6 of the 10 most frequently cited publications, and the rest consisted of reviews. The most frequent keywords for publications since January 1, 2014 were “prevention” and “management,” indicating that a number of prevention and management measures have been developed to regulate the use of denosumab in treating osteoporosis. Our research provided a comprehensive review of denosumab-related publications, suggesting that the development of denosumab is a long process and numerous clinical trials have been conducted before applications in clinical settings. Lippincott Williams & Wilkins 2023-01-27 /pmc/articles/PMC9876013/ /pubmed/36705356 http://dx.doi.org/10.1097/MD.0000000000032784 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 7400
Jiang, Xiaohong
Xie, Tianyu
Feng, Wenyu
Qin, Zhaojie
Liao, Shijie
Liu, Yun
Lu, Shenglin
He, Mingwei
Wei, Qingjun
Trends of denosumab-related publications in web of science
title Trends of denosumab-related publications in web of science
title_full Trends of denosumab-related publications in web of science
title_fullStr Trends of denosumab-related publications in web of science
title_full_unstemmed Trends of denosumab-related publications in web of science
title_short Trends of denosumab-related publications in web of science
title_sort trends of denosumab-related publications in web of science
topic 7400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876013/
https://www.ncbi.nlm.nih.gov/pubmed/36705356
http://dx.doi.org/10.1097/MD.0000000000032784
work_keys_str_mv AT jiangxiaohong trendsofdenosumabrelatedpublicationsinwebofscience
AT xietianyu trendsofdenosumabrelatedpublicationsinwebofscience
AT fengwenyu trendsofdenosumabrelatedpublicationsinwebofscience
AT qinzhaojie trendsofdenosumabrelatedpublicationsinwebofscience
AT liaoshijie trendsofdenosumabrelatedpublicationsinwebofscience
AT liuyun trendsofdenosumabrelatedpublicationsinwebofscience
AT lushenglin trendsofdenosumabrelatedpublicationsinwebofscience
AT hemingwei trendsofdenosumabrelatedpublicationsinwebofscience
AT weiqingjun trendsofdenosumabrelatedpublicationsinwebofscience